Dosage Schedule
| Cycle time | Amount per use | Frequency |
|---|---|---|
| Weeks 1–2 | 200 mcg (0.2 mg) | Once daily |
| Weeks 3–4 | 400 mcg (0.4 mg) | Once daily |
| Weeks 5–8+ | 600 mcg (0.6 mg) | Once daily |
Reconstitution Steps
- Use a sterile syringe to draw the validated diluent volume specified by the selected vial-format table, product label or approved laboratory method.
- Inject the diluent slowly down the inside wall of the vial; avoid directing the stream onto the material and avoid foaming.
- Gently swirl or roll until fully dissolved. Do not shake.
- Label the vial with product, concentration, diluent, preparation date and operator; protect from light and refrigerate at 2–8 °C (35.6–46.4 °F) unless the product-specific method states otherwise.
- Use within the product-specific validated hold time and no later than 4 weeks after preparation unless published stability data supports a different period.
Injection Technique
Use this technique only when the product-specific approved label or authorized research protocol specifies subcutaneous administration and trained personnel are responsible for the procedure.
- Clean the vial stopper and the selected administration site with alcohol; allow both surfaces to dry completely.
- Pinch a small fold of skin and insert the needle into the subcutaneous tissue at a 45–90° angle.
- Do not aspirate during a subcutaneous injection; deliver the validated volume slowly and steadily.
- If the approved protocol specifies a volume greater than 1.0 mL, divide it between separate sites rather than using one site.
- Rotate sites systematically; commonly referenced subcutaneous sites include the abdomen, thigh and upper arm.
- Wait several seconds after delivery before withdrawing the needle to help ensure the complete validated volume is delivered.
- Discard the used syringe immediately in an approved sharps container; never recap or reuse it.
Supplies Needed
- Product vial (BPC-157; use the selected labelled vial strength).
- U-100 insulin syringe (1 mL capacity) or the sterile administration device specified by the approved protocol.
- Validated diluent in the container size specified by the product label or authorized preparation method.
- Alcohol swabs and an approved sharps container—use a fresh swab for the vial stopper and each administration site.
Storage Instructions
Proper storage helps maintain product quality and stability. The supplied label, COA and product-specific validated method take precedence over these general handling rules.
- Unopened: Keep the vial sealed, dry and protected from light at the temperature stated on the supplied label; do not assume a universal shelf life.
- After preparation: Refrigerate at 2–8 °C (35.6–46.4 °F) unless the product-specific method states otherwise, and use only within its validated in-use period.
- Before opening a cold vial, allow the sealed container to equilibrate as required by the method so condensation does not enter the product.
- Long-term storage: Freeze or aliquot only when supported by product-specific stability data; avoid repeated freeze–thaw cycles and discard material with unexpected particles, discoloration or container damage.
How This Works
BPC-157 is a synthetic 15-amino-acid peptide corresponding to a sequence associated with gastric proteins. Most research is preclinical and examines nitric-oxide signaling, angiogenesis, extracellular-matrix regulation and tissue-repair models; controlled human evidence remains limited.
Chemical identity or a proposed mechanism does not establish an effective amount, treatment indication or safe human-use protocol.
Benefits & Side Effects
Benefits
- Preclinical repair research: Animal and cell studies examine BPC-157 in gastrointestinal protection, tendon and ligament healing, angiogenesis and inflammatory signaling.
- Evidence status: These findings have not been confirmed by adequate controlled human trials, and no clinical benefit is established.
Side Effects & Evidence Limits
- Human safety unknown: Adverse-event frequency, interactions, contraindications and long-term effects are not adequately characterized in humans.
- Repair-pathway uncertainty: Effects on angiogenesis and tissue signaling could be context-dependent and require formal safety evaluation.
This material is provided for educational and laboratory reference only. It is not medical advice, a clinical protocol, or a recommendation for human or veterinary administration. Consult qualified professionals and applicable regulations before planning research.